Vertex Granted Rights to Utilize TPD² for Gene Editing Therapy Development
Million Upfront Payment, Option Agreements for Three DACs Developed Using TPD²
스피드 바카라 사이트 Therapeutics (CEO Seung-Joo Lee) announced on July 16th a global multi-target license and option agreement with Vertex Pharmaceuticals. Under this agreement, Vertex will leverage 스피드 바카라 사이트's Dual-Precision Targeted Protein Degradation (TPD²) technology to research and identify new pre-treatment agents for gene-editing therapies.
Upon completion of the research period for each target, Vertex will have the option to obtain a global exclusive license for the degrader-antibody conjugates (DAC) developed using 스피드 바카라 사이트’s TPD² technology. This includes rights for research, development, manufacturing, and commercialization of the DAC.
According to the agreement, 스피드 바카라 사이트 will receive an upfront payment of million, with additional options and milestone payments of up to 0 million for up to three DACs. 스피드 바카라 사이트 will also receive tiered royalties on global annual net sales post-commercialization. Vertex will be responsible for all research, development, and commercialization activities.
Seung-Joo Lee, CEO of 스피드 바카라 사이트 Therapeutics, stated, "Vertex is a leader in discovering and developing innovative medicines and has the distinction of having the first FDA-approved CRISPR/Cas9 gene-editing therapy. We are delighted they have chosen to use 스피드 바카라 사이트's TPD² technology to discover new pre-treatment agents. This agreement opens the possibility for our pioneering targeted protein degradation approach to treat patients with new disease indications."
Vertex, which dominates the cystic fibrosis market, recorded sales of .87 billion last year. Notably, they launched 'CASGEVY,' the first CRISPR/Cas9-based treatment for sickle cell disease last year, establishing a new foothold in novel modality research and development.
스피드 바카라 사이트 Therapeutics specializes in developing DACs, considered a new modality, and focuses its research and development efforts around its TPD² platform technology. Last November, the company transferred 'ORM-6151,' a GSPT-targeted DAC based on an anti-CD33 antibody, to Bristol-Myers Squibb (BMS) under a licensing agreement valued at 0 million, receiving 0 million as an upfront payment.